About Rosetta Genomics
Rosetta Genomics is a company based in Philadelphia (United States) founded in 2000 was acquired by Genoptix in December 2017. Rosetta Genomics has raised $4 million across 9 funding rounds from investors including Teva Pharmaceuticals, Prometheus Laboratories and European Union. Rosetta Genomics operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Philadelphia, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
Teva Pharmaceuticals
& 14 more
-
Employee Count
Not available
-
Acquired by
Genoptix
(Dec 15, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Rosetta Genomics
Rosetta Genomics has successfully raised a total of $4M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rosetta Genomics
Rosetta Genomics has secured backing from 15 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Teva Pharmaceuticals, Prometheus Laboratories and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are targeted in Israel and the US.
|
Locked | Locked | Locked | |
|
Diagnostics and therapeutics for gastrointestinal and personalized medicine are developed.
|
Locked | Locked | Locked | |
|
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals.
|
Locked | Locked | Locked |
Investor details for Rosetta Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rosetta Genomics
Investment portfolio details for Rosetta Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rosetta Genomics
Detailed financials for Rosetta Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rosetta Genomics Comparisons
Peer comparison for Rosetta Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rosetta Genomics
Rosetta Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Rosetta Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rosetta Genomics
Complete news archive for Rosetta Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rosetta Genomics
Rosetta Genomics was founded in 2000 and raised its 1st funding round 5 years after it was founded.
Rosetta Genomics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Rosetta Genomics is a funded company, having raised a total of $4M across 9 funding rounds to date.
RosettaGX develops genetic tests for cancer. It offers a variety of proprietary assays that use FISH, miRNA analysis and next-generation sequencing. Its Cancer Origin Test enables physicians to discover the exact source of cancers of unknown origin. OncoGxOne and OnocGxLung use next generation sequencing for genomic profiling solid tumors and lung cancer. Reveal uses advanced miRNA expression analysis to determine necessity of surgery for thyroid cancer. In addition, the company also provides FISH and PCR assays for lung, prostate, bladder, breast and kidney cancers.
Rosetta Genomics's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Rosetta Genomics has 15 investors. Key investors include Teva Pharmaceuticals, Prometheus Laboratories, European Union, Kadimastem, and Genoptix.